Business

John Poss, Chief Executive Officer of GB Sciences, Inc., Returns to Uptick Newswire’s “Stock Day” Podcast with Everett Jolly for Operational Update

John Poss, Chief Executive Officer of GB Sciences, Inc., Returns to Uptick Newswire’s “Stock Day” Podcast with Everett Jolly for Operational Update.

articleGb Sciences, Inc.February 6, 20185/company/gb-sciences-inc/news/john-poss-chief-executive-officer-of-gb-sciences-inc-returns-to-uptick-newswires-stock-day-podcast-with-everett-jolly-for-operational-update
John Poss, Chief Executive Officer of GB Sciences, Inc., Returns to Uptick Newswire’s “Stock Day” Podcast with Everett Jolly for Operational Update

About this update from Gb Sciences, Inc.

[{"type":"text","content":"\n\n PHOENIX, Feb. 06, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB:GBLX) (the “company”), discusses 2017 achievements and 2018 operations expectations, on Stock Day Podcast with Everett Jolly.\n “It is great to have GB Sciences Inc. back on the show,” said Jolly.  “The stock has done tremendously in recent months and monthly revenues are increasing.” GB Sciences Inc., is a science oriented cannabis company working with top scientist in the industry to develop evidence based compounds to treat specific diseases. The company’s growth strategy, based on three areas of focus, has allowed GB Science to develop recurring revenue streams, grow geographically, and make progress scientifically. John Poss commented, “We are thrilled to be making strides to help patients who suffer from multiple diseases. We are using our work in biotech and genetics to propagate specific strains of cannabis that we believe will target conditions like Parkinson’s and heart disease.” The company currently holds multiple provisional patents and will embark on patient trials in the year to come. To view the interview in its entirety, click here: https://upticknewswire.com/featured-interview-ceo-john-poss-of-gb-sciences-inc-otcqb-gblx-3 About GB Sciences, Inc.GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com. Forward-Looking StatementsThis press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.&#16...

More updates from Gb Sciences, Inc.